Last reviewed · How we verify
NCT04340024
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
trial in Nasopharyngeal Cancer in 5,000 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | National Cancer Centre, Singapore |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 30 September 2015 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Singapore |
Conditions studied
- Nasopharyngeal Cancer — all drugs for Nasopharyngeal Cancer →
- Prostate Cancer — all drugs for Prostate Cancer →
- Other Cancer — all drugs for Other Cancer →
Sponsor
National Cancer Centre, Singapore
Who can join
Adults 21 to 99, any sex, with Nasopharyngeal Cancer or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis.
Schack LMH, Naderi E, Fachal L, Dorling L, et al · · 2022 · cited 15× · PMID 35039627 · DOI 10.1038/s41416-021-01670-w -
Radiation therapy with phenotypic medicine: towards N-of-1 personalization.
Chong LM, Wang P, Lee VV, Vijayakumar S, et al · · 2024 · cited 5× · PMID 38514762 · DOI 10.1038/s41416-024-02653-3 -
The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care.
Sindhu KK, Dovey Z, Thompson M, Nehlsen AD, et al · · 2024 · cited 2× · PMID 38633827 · DOI 10.1002/bco2.323 -
Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes.
Yeo ELL, Hong BH, Tay SH, Neo J, et al · · 2025 · cited 1× · PMID 40412382 · DOI 10.1016/j.xcrm.2025.102143
Verify or expand the search:
- PubMed search for NCT04340024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasopharyngeal Cancer
Currently open trials in the same condition.
- NCT06749899 — QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. · Phase 3 · recruiting
- NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting
- NCT06349889 — Adebrelimab and Chemoradiotherapy in High-risk LANPC · Phase 2 · recruiting
- NCT06414577 — Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma Af · Phase 2 · active not recruiting
- NCT05983432 — Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors · Phase 1 · recruiting
Other National Cancer Centre, Singapore trials
Trials by the same sponsor.
- NCT07428356 — Histotripsy for Ablation of Liver Tumours in Asia · NA · recruiting
- NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting
- NCT07116161 — Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore · NA · recruiting
- NCT06977360 — Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solutio · NA · recruiting
- NCT06766058 — Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04340024 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Centre, Singapore
- Last refreshed: 11 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04340024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing